Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003666 · ClinicalTrials.gov registry record · Phase 2
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00003666 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 36 participants.
The verdict
NCT00003666, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or refractory non-small cell lung cancer.
Interventions
- DRUG 6-hydroxymethylacylfulvene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1998-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003666
The ClinicalTrials.gov registry entry for NCT00003666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6-hydroxymethylacylfulvene is the first listed.
NCT00003666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003666 about?
NCT00003666 is a clinical study titled "Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or refractory non-small cell lung cancer.
What is the current status of trial NCT00003666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1998-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00003666?
The interventions under investigation include: 6-hydroxymethylacylfulvene (DRUG).
Who is sponsoring clinical trial NCT00003666?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.